Manufacturing Lead (Hardware)
Mytos automates the production of stem cell-derived regenerative medicines using proprietary robotics, backed by a $19M Series A and Y Combinator. They're hiring a Manufacturing Lead for hardware in London, working on-site to scale the custom robotics behind its iDEM platform. This hardware engineering role sits within the UK's biomanufacturing and lab automation sector.
About Us
You rarely get the chance to change an entire industry. But that's the position we find ourselves in. Join us, and you'll help scale cures to patients that need them sooner.
We've developed fully-automated cell manufacturing sites, powered by custom robotics - to scale treatments to millions of patients. Last year, patients were cured of diseases like Parkinson's and vision loss using stem-cell derived cells - but today these Regenerative Medicines are produced by hand, meaning they're too expensive and hard to scale.
With our automated manufacturing sites, these therapies can now be scaled globally at low cost. We've announced partnerships across multiple therapies so far ranging from Parkinson's, to hearing loss, to bone repair - and raised $24m to expand into the market faster, and accelerate our development! Within the next 12 months, neurons grown on our machines will be going into Parkinson's patient brains.
We've assembled a world-class team to take on this challenge, with ex-Dyson engineers and Nature-published scientists working hand-in-hand. Mytos is backed by Y Combinator, the most successful startup program in the world which produced companies such as AirBnb, Dropbox, and Ginkgo Bioworks.
About Mytos
Mytos automates the production of stem cell-derived regenerative medicines using proprietary robotics. Founded in 2016 by Ali Afshar and Ignacio Willats, who met during Afshar's PhD at Imperial College where he became frustrated by manual laboratory processes and began building robots to automate repetitive tasks. The platform takes stem cells (iPSCs) and fully automates their differentiation into specific cell types such as neurons and cardiac cells, replacing manual touchpoints with precisely controlled, programmable steps. In 2023, Mytos closed a $19M Series A led by Buckley Ventures, joined by IQ Capital and Wing VC. The company has launched its iDEM platform as an automated contract development and manufacturing organisation, with its first facility at the Cell and Gene Therapy Catapult's Stevenage Manufacturing Innovation Centre targeting clinical readiness by September 2026.